INTRODUCTION
Phenol was discovered in 1834 and has been used for the treatment of spasticity since the 1960s. Phenol causes nerve destruction (neurolysis) by inducing protein precipitation. The nerve-ending regeneration following phenol injection is a very long process (6 months to years). The damage to the nerves tends to block the messages from nerve to a muscle preventing muscle contraction. This leads to the reduction of the spasticity in the treated muscle (motor points block) or muscles supplied by a motor nerve (nerve block).
Spasticity can affect the ability to feed and dress oneself, bladder and bowel control, hygiene, and mobility (e.g. walking and transferring oneself)1. It also predisposes to complications such as pressure sore formation, seating difficulties, and contractures1. The emotional and social impact upon affected individuals can lead to depression, social withdrawal, interruption of lifestyle, and isolation. These often require larger amounts of care and social support.
Treatment of spasticity depends on effects of spasticity on the function as well as posture. The treatment process starts with actively looking for and then treating the triggering factors such as pressure sores, infections, constipation, bladder dysfunctions. The multidisciplinary team makes the decision to treat spasticity. The treatment options are; physical (posture management, splints, physiotherapy), medical (oral antispasmodic agents, botulinum toxins, phenol/alcohol nerve blocks and motor point blocks, intrathecal phenol, intrathecal baclofen) and surgical (orthopaedic and neurosurgical procedures).
The side effects of phenol motor point and nerve blocks are uncommon and include the following, bruising or haematoma at the injection site, pain at the injection site, disturbance of sensation, and neuropathic pain.
Materials and Methods
A comprehensive spasticity assessment was carried out in the general rehabilitation/spasticity clinic and treatment plan agreed with the patient. Patients who accepted the procedure were then appointed to phenol spasticity clinic. For lower limb spasticity phenol nerve and motor point blocks were considered in combination with the oral antispasmodic agents such as gabapentin, baclofen, tizanidine, and dantrolene. For all the ambulant patients a trial block with local anaesthetics was performed in the first instance, and phenol block was only offered if the trial block was successful. For upper limb spasticity phenol, nerve/motor point blocks were used for patients that did not respond to botulinum toxin injections, or botulinum toxin injections were contraindicated, or where there was formation of antibodies against the botulinum toxin. A combination of phenol nerve/motor point blocks with botulinum toxin was considered in patients with multifocal spasticity involving two or more than two limbs or several groups of muscles within one limb. A record of all the complications associated with the procedures was maintained.
Results
A total of 54 patients were treated at the clinic between July 2014 and December 2015. The minimum age was 17 and maximum age of 83 years with a mean age of 49.6 and a median of 51.5 years. There were 24 (44.4%) males and 30 (55.6%) females ( Figure 1 ).
Ischemic stroke was the most common diagnosis present in 26.9% of the patients followed by multiple sclerosis in 24.1%. The detailed breakdown of the diagnosis is shown in (Figure 2 ).
A total of 86 procedures were performed during July 2014 to December 2015. Out of these 70 (79.5%) were performed using phenol whereas 16 (20.5%) were trial local anaesthetics blocks (either nerve or motor point blocks). The most frequently performed procedure was posterior tibial nerve block (52.3%) followed by Obturator nerve block (25.5%), rectus femoris motor point blocks (6.9%), hamstrings motor point blocks (5.8%), elbow flexor motor point blocks (4.6%), gastrocnemius motor point blocks (2.3%), wrist flexors motor point blocks (1.2%) and wrist extensors motor point block (1.2%). These are shown in Table 1 . Twenty-one (24.4%) procedures were performed on the right side, 32 (37.2%) were on the left, and 33 (38.4%) procedures were bilateral (Figure 2 ).
Five percent aqueous phenol was used for the procedures. The minimum volume of aqueous phenol used on one side was five ml and the maximum was 10 ml. The maximum volume of aqueous phenol used on both sides was 20 ml.
There were only 4 (4.6%) complications noted related to 86 procedures. One patient (1.2%) complained of bruising and pain at the injection site, which was transient and lasted only for few days and resolved spontaneously. One patient (1.2%) developed transient bruising without pain at the injection site. Similarly, 1 (1.2%) patient developed transient muscle spasms and neuropathic pain for few days following the posterior tibial nerve block. This also resolved within days following the injection. One (1.2%) patient who underwent a trial posterior tibial nerve block with local anaesthetics developed weakness in her ankle plantar flexors that prevented her from driving for 24 hours (Table 2) . We did not proceed to definitive phenol block following the trial. It is noteworthy that all the complications were with the posterior tibial nerve block. 
Discussion
Spasticity is a motor disorder that is characterized by a dynamic increase in muscle tone, resulting in hyperexcitability of the stretch reflex as a component of upper motor neuron syndrome 2 . Spasticity occurs when there is relative over-excitation of the alpha motor neuron due to the absence of descending inhibitory signals. However, it is also well documented in the literature that absence of descending inhibition is not the sole responsible factor in the pathophysiology of spasticity. The increased afferent input to the spinal motor neurons due to increased sensitivity of the muscle spindle 3 as well as changes in the intrinsic properties of the neuron leading to self-sustained firing in response to stretch reflex 4 play a significant role in spasticity development in upper motor neuron lesions. Recent data has also suggested that there are changes in the mechanical properties of the spastic muscle, physiological changes in the tendon compliance and muscle fibers 5, 6 . These physiological changes are gradual and can contribute to muscle stiffness as well as the formation of contractures in the spastic muscles.
Phenol has been traditionally used to treat spasticity. However, it has been replaced by botulinum toxin in recent years. The phenol nerve blocks are longer lasting and cheaper in comparison to botulinum toxin 7 . It can also be used in combination with botulinum toxin because of the dose limitation of the toxin. This gives a greater flexibility to treat more muscle groups on the same occasion. In our clinical practice, the first line of treatment for lower limb spasticity is phenol and botulinum toxin is considered where there is no effect from phenol blocks. For the upper limb, phenol is used only if there is no effect from botulinum toxin or patients are not able to tolerate the toxin due to side effects.
The side effects of phenol are rare, and the injections are normally well tolerated 8 .
If the patient moves or the limb jerks rapidly while the needle is in the muscle, then there may be some muscle tearing with the formation of bruise or haematoma. This may produce considerable swelling and in the lower limb, which may mimic a deep vein thrombosis. It is, therefore, imperative that this should not be treated with anti-coagulation but with general supportive measures such as ice, rest, and elevation of the involved limbs. Haematoma can lead to contractures 9 . In our study there was no haematoma formation. However, one patient developed superficial bruise that resolved spontaneously.
The injection is rarely painful, although there may be a severe burning pain at the time of the injection and a chance of developing deafferentation pain 9 . This has been observed in our study.
If sensory nerve or fibres are affected by the injection, then hyperesthesia and burning pain may develop. These may last weeks or months and in theory, it could be permanent. However, this usually, settles without any treatment. Still if persisting it could be treated with anti-neuropathic medications. There was only one case of neuropathic pain in our study that resolved spontaneously. However, it is in our clinical practice to alert patients to the possibility of this complication and the fact that pain could be permanent during the informed consenting process. Lee Spasticity may not always be harmful. It may help the individuals to mobilize or transfer by maintaining the postural control. In such cases reducing spasticity may have a harmful effect on the quality of life. Treatment of spasticity is only considered when it is interfering with the functionality, quality of life and becoming painful. The goals of treatment of spasticity should always be clearly defined and agreed with the patient. In our clinical practice, any patients who can mobilize, transfer independently would be considered for a trial block with a local anaesthetic before proceeding to a phenol nerve or motor point blocks. In our study one patient was not able to drive following her trial posterior tibial nerve block. The effect of local anaesthetic lasted for 72-hours so the patient declined to have the phenol posterior tibial nerve block afterwards.
Conclusion
Phenol nerve and motor point blocks have been used to treat spasticity for many years. These are safe procedures with very low complications rate. The effects of the block may last from few weeks to months. The technique is safe to be used as an outpatient procedure, and the results are usually immediate.
